Loading
A phase 1/2 trial of CM350 group1 in advanced solid tumours, run by Keymed Biosciences Co.Ltd, now recruiting.
A Study of CM350 in Patients With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT05263960 by Keymed Biosciences Co.Ltd, with 248 participants planned, started 2022-04-21 and due to reach its primary completion in 2027-04. Interventions recorded: CM350 group1, CM350 group2 and CM350 group3.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Keymed Biosciences (KYM Biosciences), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Keymed Biosciences (KYM Biosciences) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/